CGC 11093

Drug Profile

CGC 11093

Alternative Names: CGC-11093; SL 11093

Latest Information Update: 24 Jul 2008

Price : $50

At a glance

  • Originator Cellgate
  • Developer Progen Pharmaceuticals Inc
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 24 Jul 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top